A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

December 28, 2021

Study Completion Date

December 28, 2021

Conditions
Rheumatoid Arthritis
Interventions
DRUG

VIB4920

liquid for IV infusion following dilution in normal saline

DRUG

Placebo

0.9% saline for IV infusion

Trial Locations (25)

16635

Research Site, Duncansville

20902

Research Site, Wheaton

27804

Research Site, Rocky Mount

28144

Research Site, Salisbury

28210

Research Site, Charlotte

30342

Research Site, Atlanta

33014

Research Site, Miami Lakes

33063

Research Site, Margate

33542

Research Site, Zephyrhills

33765

Research Site, Clearwater

36207

Research Site, Anniston

40504

Research Site, Lexington

45377

Research Site, Vandalia

73069

Research Site, Norman

75231

Research Site, Dallas

77477

Research Site, Baytown

85704

Research Site, Sun City

91786

Research Site, Upland

Unknown

Research Site, Poznan

Research Site, Krakow

Research Site, Nadarzyn

Research Site, Siedlce

Research Site, Bialystok

Research Site, Elblag

Research Site, Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT04163991 - A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter